SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
FATE

Fate Therapeutics Inc (NASDAQ:FATE)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$0.92-$0.09 (-9.01%)
 
Market cap
$107M
Insider Score
Health Score
Analyst consensus
Listed since
Oct 1, 2013
Market Cap$107.12M-10.8%
Revenue (ttm)$4.75M-33.4%
Net Income-$124.43M+20.3%
EPS-$1.03+22.0%
Shares Out116.56M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3,703,250
Open$1.01
Previous Close$1.01
Day's Range$0.90 - $1.02
52-Week Range$0.90 - $3.23
Beta2.67
AnalystsBuy
Price Target$6.17(+571.38%)
Earnings DateFeb 25, 2027

About FATE

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs. Key candidates include FT516, which targets acute myeloid leukemia (AML), B-cell lymphoma, and advanced solid tumors; FT596 for B-cell lymphoma and chronic lymphocytic leukemia; FT538, addressing AML and multiple myeloma; FT576, also focused on multiple myeloma; FT819, aimed at both hematologic malignancies and solid tumors; FT536, another program for solid tumors; and FT500, intended for advanced solid tumors. The company also actively engages in strategic collaborations to advance its research and development. It holds an agreement with Ono Pharmaceutical Co. Ltd. for the joint development and commercialization of two novel, "off-the-shelf" iPSC-derived CAR T-cell therapies. Furthermore, Fate Therapeutics maintains a research collaboration and licensing deal with Juno Therapeutics, Inc., focusing on identifying small molecule modulators that can enhance the therapeutic efficacy of genetically engineered T-cell immunotherapies. A separate collaboration and option agreement exists with Janssen Biotech, Inc. Established in 2007, Fate Therapeutics, Inc. is based in San Diego, California.

Address
12278 Scripps Summit Drive, San Diego, CA, 92131, US
Market Cap
107 million
Employees
161
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$336.34K
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
1 Buy1 Hold0 SellAvg target $7.00 (+661.7%)

2 firms rating FATE in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Weak
From FATE’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-9.01%
5 Days
-27.64%
1 Month
-55.60%
6 Months
-56.24%
1 Year
-10.78%

$FATE stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in FATE holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by FATE's directors and management

Net Shares Purchased by Insiders−90k−45k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

FATE Estimated quarterly lobbying spending

Source: U.S. Senate LDA

FATE Revenue by Segment

$55.13MTotal
Less:$32.25M58.50%
Personnel costs$9.65M17.51%
Clinical programs$7.50M13.61%
Facilities costs$4.58M8.31%
Research activities$992.00K1.80%
Change in fair value of stock price appreciation milestones$151.00K0.27%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New FATE patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to FATE from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in FATE

VTIVanguard Morningstar Total Stock Market ETF$5.24M
VXFVanguard Extended Market ETF$2.50M
CNCRLoncar Cancer Immunotherapy ETF$893.63K
VHTVanguard Health Care ETF$596.89K
SCHASchwab U.S. Small-Cap ETF$544.18K
IWCiShares Micro-Cap ETF$353.71K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from FATE’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
60% of score
0
Analyst Ratings
40% of score
85
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
0
Sells
7
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

CNCRLoncar Cancer Immunotherapy ETF3.33%
JFWDJacob Forward ETF0.88%
QQQSInvesco NASDAQ Future Gen 200 ETF0.38%
BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF0.21%
STSBiShares Factors US Small Blend Style ETF0.19%
JHMHJohn Hancock Multifactor Health Care ETF0.10%
VHTVanguard Health Care ETF0.00%

Weight is the stock’s share of each fund’s holdings.